Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2001

View Archived Issues

New class of compounds found active against hepatitis C

NIH awards Antigenics grant to support development of malaria vaccine

Vasogen commences chronic lymphocytic leukemia clinical trial in Canada

Milestone payment received by Adolor from GSK for dermal ADL-2-1294

Epothilone B derivative CGP-85715 characterized in vitro and in vivo

PNU-252808 associated with blockade of cell cycle progression and induction of apoptosis

Cardioprotective effects of new antioxidant discussed at Kyoto meeting

Genetronics reports promising results from phase II trials of EPT technology

E.C. approves Novartis's Starlix for type 2 diabetes

Novel probes for the dopamine transporter designed at NIDA

Atrix grants European marketing rights for Leuprogel to MediGene

DuPont describes efforts to design improved antipsychotic agents

Ortho-Clinical Diagnostics and Caprion to develop blood test for vCJD

SR-374: a new DuPont compound with potent and selective anti-factor Xa activity

Different doses of toborinone evaluated for electrophysiological effects in dogs

Efficacy and lack of CNS adverse effects reported for Adolor analgesic

Preclinical study results for JTV-519 discussed in Kyoto

InKine awarded NIH grant to support angiogenesis inhibitor research

Japanese approval of Zyvox marks achievement of regulatory milestone

Axonyx's phenserine regulates APP processing in preclinical study

Multiprotein AIDS vaccine provides high-level protection in monkeys, advances toward human trials

Inhibitors of MTP and their potential uses described by Boehringer Ingelheim

New serotonergic compounds described as particularly useful for depression, memory disorders

Bertek licenses beta-blocker nebivolol; new indications to be evaluated

Merck presents new group of integrin antagonists in recent patent

Bicyclic RAR agonists from Roche described as useful for emphysema and related disorders

Pfizer reports hydroxamic acid-based selective aggrecanase inhibitors

Canadian-Japanese team discovers new cytokine inhibitors

Inhibitors of NO production claimed for MS, RA, CHF and dilated cardiomyopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...